FISHMAN BARRY 4

What Happened Barry Fishman, a director of Medicus Pharma Ltd. (MDCX), received an award of 25,000 derivative shares on March 30, 2026. The grant is reported as an "A" transaction (award/grant) with an acquisition price of $0.00 per share (total recorded value $0), consistent with a compensation or director equity award rather than an open-market purchase.

Key Details

• Transaction date: 2026-03-30 (award/grant, transaction code A)
• Report filed: Form 4 dated 2026-04-01 (filed within the usual two-business-day reporting window)
• Shares acquired: 25,000 derivative shares at $0.00 per share (total $0 as recorded)
• Shares owned after transaction: Not specified in the provided excerpt
• Footnotes/plan references: None noted in the provided data (no 10b5-1 plan or tax-withholding details shown)

Context An "A" code award typically reflects compensation (e.g., restricted stock units or other equity grant) and does not necessarily indicate a personal cash investment or a sale. Such grants are common for directors and are different from open-market purchases (bullish signal) or sales (liquidity-taking). This filing appears timely based on the dates provided.